The α 1A -AR is thought to couple predominantly to the Gα q /PLC pathway and lead to phosphoinositide hydrolysis and calcium mobilization, although certain agonists acting at this receptor have been reported to trigger activation of arachidonic acid formation and MAPK pathways. For several G protein-coupled receptors (GPCRs) agonists can manifest a bias for activation of particular effector signaling output, i.e. not all agonists of a given GPCR generate responses through utilization of the same signaling cascade(s). Previous work with Gα q coupling-defective variants of α 1A -AR, as well as a combination of Ca 2+ channel blockers, uncovered cross-talk between α 1A -AR and β 2 -AR that leads to potentiation of a Gα q -independent signaling cascade in response to α 1A -AR activation. We hypothesized that molecules exist that act as biased agonists to selectively activate this pathway. In this report, isoproterenol (Iso), typically viewed as β-AR-selective agonist, was examined with respect to activation of α 1A -AR. α 1A -AR selective antagonists were used to specifically block Iso evoked signaling in different cellular backgrounds and confirm its action at α 1A -AR. Iso induced signaling at α 1A -AR was further interrogated by probing steps along the 
Introduction
Adrenoceptors (AR) belong to the large family of G protein-coupled receptors (GPCRs), also known as seven-transmembrane receptors (7-TMRs), which transduce extracellular stimuli into cellular responses. Adrenoceptors respond to the endogenous catecholamines norepinephrine and epinephrine, and mediate critical functions of the central and peripheral nervous systems. They were initially subdivided into two main types, a-and b-, based on the rank orders of potency of norepinephrine, epinephrine and Iso as well as the physiological outcome of the response (contraction vs. relaxation) [1, 2] . With the discovery of new synthetic and more selective ligands, new receptor subtypes have been identified within each of the two groups. b-AR now includes b 1 , b 2 , and b 3 -subtypes while a-is subdivided into a 1 -and a 1 - [3] [4] [5] [6] . Introduction of molecular cloning confirmed the existence of these genetically and pharmacologically distinct subtypes of b-AR and allowed a final classification of the a 1 -subgroup into a 1A -, a 1B -and a 1D - [7] and a 1 -into a 2A -, a 2B -and a 2C - [8] ARs.
Iso has been one of the most commonly used agonists for differentiation of a-and b-ARs. At low concentrations (1-100 nM) Iso causes smooth muscle relaxation through its action at b-ARs, a property that prompted its introduction for the treatment of asthma, chronic bronchitis and emphysema. Even though very selective for the b-AR class, several groups reported that Iso, at high doses (4 mM and higher) also evoked a-mediated responses leading to the contraction of smooth muscles of rabbit aorta and posterior vena cava as well as of rat vas deferens [9] [10] [11] [12] [13] [14] . High doses of Iso were also shown to increase blood pressure in rabbits [1] , and cause arterial hypertension in anesthetized cats and dogs [15, 16] . The involvement of a-AR in mediating the physiological effects of Iso was implicated in these and other studies by the ability of antagonists dibenamine, phenoxybenzamine or phentolamine to block responses [11, 14, 15] .
More recently, observations of Ca 2+ mobilization responses in rat parotid acinar cells in response to high concentrations of Iso (1-200 mM) led to a long running debate of how Ca 2+ is involved in cAMP-mediated amylase release, and whether this response is mediated solely by b-AR [17, 18] . Subsequent studies in rat parotid acinar cell preparations revealed prazosin sensitivity for the Iso-mediated Ca 2+ mobilization response, indicating Iso activation of a-AR [19, 20] although the subtype involved was not identified. Thus, although compelling historical precedents exist for Iso agonism at a 1 -ARs, no studies focused on the signaling mechanisms or a 1 -AR receptor sub-types involved. The use of Iso in basic and clinical studies would clearly benefit from greater mechanistic understanding of Iso-mediated signaling via a-ARs. Iso binds with relatively high affinity to all three b-AR subtypes (K i : 0.22 mM at b 1 -, 0.46 mM at b 2 -and 1.6 mM at b 3 -AR in presence of GTP; 0.02 mM at b 2 -AR in its absence [21, 22] ), acting as a high intrinsic efficacy (full) agonist. Thus, Iso-bound b-AR couples to Ga S leading to stimulation of adenylyl cyclase, cAMP production, and phosphorylation of protein kinase A (PKA). In addition to the activation of this "canonical" pathway, Iso is highly efficacious at inducing b 2 -AR mediated signaling via G-protein coupled receptor kinases-(GRK) and b-arrestin. This leads to receptor phosphorylation, recruitment of c-Src and activation of MAPK signaling pathways among others (reviewed in [23] .
It has also been shown that Iso at higher doses (above 100 nM) induces G proteinindependent signaling at b 2 -ARs [24] . In mouse embryonic fibroblasts (MEFs), stimulation of b 2 -AR by Iso results in a biphasic concentration-dependent increase in extracellular signalregulated protein kinase (ERK) activity. The high potency phase was found to be dependent on Ga S while the low potency phase was not. Sun et al. combined the use of MEF cells from various knock-out mice with biophysical studies testing the interaction of the purified components (b-AR and Src) to show that the low potency phase reflects direct interaction and activation of Src by the Iso-activated b 2 -AR. The high concentrations of Iso used in this and several other studies [18, 25, 26] may also lead to activation of a-ARs with signaling consequences that are not well-characterized at the molecular level. Thus, there is a great need to explore the mechanism of Iso signaling through a-ARs.
We investigated the Iso initiated signaling in transiently transduced HEK-293/EBNA cells expressing quasi-physiological levels of a 1A -AR. Since HEK-293 cells endogenously express b 2 -AR, this system gave us the ability to monitor Iso activation of several cellular events in the presence and absence of a 1A -AR [27] . In untransduced cells, we observed Iso-induced monophasic cAMP and ERK activation as well as Ca 2+ mobilization with efficacy within the range expected for this agonist acting at b 2 -AR. In contrast, in cells transiently transduced with a 1A -AR, Iso evoked biphasic concentration-dependent activation of ERK activity as well as Ca 2+ mobilization. The high potency phase of the concentration-effect relation was sensitive toa b 2 -selective antagonist, while the low potency phase was blocked by application of a 1A -AR-selective antagonists. Iso was found to be an agonist at recombinantly expressed a 1A -AR subtype in a manner which recruits signaling mechanisms distinct from those seen with NE or selective a 1A -AR agonists. Our data suggest that Iso induces a a 1A -AR-mediated signaling mode biased toward MAPK/ERK and likely independent Ga q . We also show evidence indicating that this signaling mode involves receptor internalization.
Materials and Methods

Materials and reagents
Reagents were purchased from the following commercial suppliers: A-61603, xamoterol, procaterol and fenoterol from Tocris (Ellisville, MO) cence relative to the baseline signal DF/F 0 = (F-F 0 )/F 0 +1 (where DF is maximal fluorescence intensity observed following agonist application, F 0 = baseline fluorescence, or average intensity measured over the 10 s interval prior to agonist application). Image acquisition rates were varied from 1 Hz during the first 100 s of measurements to 0.5 Hz for the remaining time of the recording.
IP and cAMP Accumulation Assays
Virally transduced HEK-293/EBNA cells were washed by centrifugation at 150 × g for 8 min, before resuspension in assay buffer (20 mM HEPES, 10 mM glucose, 1.8 mM CaCl 2 , 0.5 mM MgSO 4 , in HBSS 1X buffer, 50 mM LiCl) at 10 8 cells/mL. Cells were placed in 384-well black polystyrene plates (Costar 3912) at 10 mL/well, and incubated with 10 mL of antagonist or vehicle at room temperature. After 10-20 minutes, 10 mL of agonist was added followed by incubation for 5 to 30 minutes. Stimulation was stopped by addition of lysis buffer. Second messenger levels were determined using a homogeneous immunoassay method with time-resolved FRET detection (IP-One HTRF, Cisbio International) according to protocols provided by the supplier. Sample fluorescence was measured with a Nanoscan plate reader (IOM, Berlin). Each data point represents the average of quadruplicate determinations and each experiment was performed at least two times independently.
Detection of IP 1 , IP 2 and IP 3 inositol phosphates
Virally transduced HEK-293/EBNA cells were resuspended in growth medium and seeded in poly-D-lysine coated 96-well black plates at a density of 100,000 cells/0.1 mL per well, Cells were allowed to attach for 2 hours at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . After that, the medium was replaced with agonist solution in assay buffer (20 mM HEPES, 10 mM glucose, 1.8 mM CaCl 2 , 0.5 mM MgSO 4 , in HBSS 1X buffer, 50 mM LiCl) and cells were incubated at 37°C for 30 min. Stimulation was stopped by exchange of assay buffer with lysis buffer (100 mL 0.1N HCl/MeOH), and lysis proceeded for 30 min at 4°C. Cellular levels of inositol phosphates were determined using a Thermo LC-MS detection system following a published protocol [29] . Chromatography was performed employing a BioBasic column AX (50 × 2.1 mm, Thermo). The mobile phase consisted of solvent A: 10 mM ammonium acetate, pH 6 in 30/70 acetonitrile/water, and solvent B: 1 mM ammonium acetate, pH 11 in 30/70 acetonitrile/water. A gradient solvent system was used starting with 0% solvent B, and analytes were eluted by increasing solvent B to 100% over 3 min. Each data point represents the average of triplicate determinations and each experiment was performed at least three times independently.
MAPK activation assays
MAP kinase activation was monitored using the bead proximity-based AlphaScreen assay to detect phosphorylated ERK (SureFire p-ERK, PerkinElmer, Boston, MA). Virally transduced HEK-293/EBNA cells were seeded in 96 well plates with serum-free growth medium at 50,000 cells/well, followed by incubation for six hours at 37°C in 7% CO 2 . Cells were then stimulated with vehicle or agonist for 5 min at 37°C in 7% CO 2 . Agonist response was terminated following rapid removal of the medium by adding 50 mL per well of SureFire lysis buffer, followed by incubation of cells for 10 min at room temperature. Plates were stored at −80 C prior to analysis for p-ERK levels. Processing of cells for phospho-ERK detection was performed using an AlphaScreen SureFire p-ERK assay kit (PerkinElmer, Boston, MA) according to specifications from the manufacturer. Briefly, 10 mL of lysate were transferred to 384 well plates (OptiPlate) and combined with 17 mL of SureFire buffer containing AlphaScreen beads. Plates were incubated for 2 h at room temperature and the fluorescence signal was recorded using a Fusion plate reader (PerkinElmer), adjusted to standard AlphaScreen settings. 
Radioligand binding studies
Data Analysis
Experiments were carried out in independent replicates (n indicated in figure legends). Graphs shown reflect either pooled or representative data (see figure legends) (Fig. 1A) . This suggested the presence of two distinct mechanisms mediating the observed Ca 2+ response. The half-maximal amplitude of the high potency phase was observed at 4.0 nM Iso, whereas the half-maximal amplitude of the lower potency phase occurred at 2.6 mM Iso ( 50 in non-transduced cells corresponds to the higher potency phase of the biphasic Iso response observed in a 1A -AR_HEK-293/EBNA cells, we used receptor-selective antagonists to further characterize the observed Ca 2+ response. The lower potency phase of response to Iso was sensitive to the highly selective a 1A -AR antagonist, RS100329 (pK B = 9.6 for a 1A -AR) (10 nM, Fig. 1B ) [32] . The magnitude of the Iso response in presence of RS100329 (DF/F 0 = 1.2) matched the magnitude of the high potency response phase observed in vehicle pretreated cells, as determined using the two-site model (DF/F 0 = 1.2). Consistent with this, the potency of Iso in the presence of RS100329 (EC 50 = 4.6 nM) corresponded well to the potency calculated for the high potency phase of biphasic dose-response curves in cells pretreated with vehicle (EC 50 = 4.0 nM, Table 1 ). This finding indicates virtually complete blocking of the low potency phase by RS100329 with no effect on the high potency phase. On the other hand, pretreatment of a 1A -AR_HEK-293/EBNA cells with the b 2 -AR selective antagonist ICI 118,551 (10 nM) resulted in monophasic concentration-response to Iso (Fig. 1B) . The calculated potency of Iso in the presence of this b 2 -AR selective antagonist (EC 50 = 2.4 mM) matched the EC 50 of 2.6 mM determined for the low potency phase of the bipasic response to Iso in vehicle-treated cells. Interestingly, the maximal response amplitude for Iso in the presence of ICI 118,551 (DF/F 0 = 1.3, estimated using a monophasic concentration-response model) was lower than the amplitude of the lower potency phase observed in vehicle treated cells (DF/F 0 * 1.5, estimated using a biphasic concentration-response model). This suggests some level of synergy when Iso simultaneously occupies a 1A -AR and b 2 -AR. The b 1 -AR selective antagonist atenolol (1 mM) had no effect on the Iso concentration-response relationship (Fig. 1B) . In untransduced HEK-293/EBNA cells, response to Iso was blocked by 10 nM ICI118551, a b 2 -selective antagonist, but not by the a 1A -AR-selective antagonist RS100329 (Fig. 1C) . Thus, the biphasic Ca 2+ transient concentration-response relationship observed with Iso seems to require co-expression of both the a 1A -and b 2 -adrenoceptors. , not found in untransduced control cells (Fig. 2B , black lines vs. solid gray trace). Because NE possesses * 10-fold higher affinity at a 1A -AR relative to b 2 -AR (K i = 3.1 mM at a 1A -AR vs. 34 mM at b 2 -AR, Table 1 ), the observed response to 100 nM NE is likely driven mostly through occupancy at a 1A -AR (Fig. 2B, dashed black (Fig. 3A) . In a 1A -AR_ HEK-293/EBNA cells, Iso-mediated responses were greatly reduced in amplitude in the absence of extracellular Ca 2+ (Fig. 3B) . However, the low potency phase of the concentration-response Iso induced Ca 2+ mobilization in α 1A -AR transduced HEK-293/EBNA cells does not reflect coupling to Gα i Receptor coupling to Ga i , the most abundant G protein a subunit, has been shown to lead to activation of PLC activity via the Gb/g subunits and thus, can lead to IP accumulation and release of intracellular Ca 2+ (Reviewed in [36] . Since this pathway is different from Ga q -mediated signaling, the kinetics of Ca 2+ mobilization may also differ. We next searched for a role for Ga i activation in response to Iso-treatment in untransduced and a 1A -AR transduced cells, pretreated for 18 hours with pertussis toxin or vehicle. Pretreatment of untransduced cells with pertussis toxin (100 ng/mL) resulted in a slight increase in the maximum amplitude of the Ca 2+ transient response at saturating concentrations of Iso (DF/F 0 = 1.5 vs. 1.7), with a negligible increase in EC 50 from 6 to 10 nM (Fig. 4A) . A similar increase was observed in the b 2 -AR-dependent phase of the Iso concentration-response curve (from DF/F 0 = 1.3 to 1.5) in a 1A -AR expressing cells, also with no change in observed potency (EC 50 = 6.6 vs. 5.6 nM) (Fig. 4B) . Since in these cells induction of cAMP leads to Ca 2+ mobilization [27] , increase in Ca 2+ mobilization following PTX pretreatment may be a result of an increase in intracellular cAMP. This observation would be consistent with previous findings indicating that b 2 -AR can couple to both Ga s and Ga i in HEK-293 [37] . On the other hand, in a 1A -AR transduced HEK-293/EBNA cells, pertussis toxin treatment did not significantly affect Ca 2+ mobilization responses to Iso (EC 50 = 2.8 vs. 2.7 mM with PTX and DF/F 0 = 1.6 vs. 1.5 with PTX), suggesting that coupling to Ga i is not necessary for this Iso-mediated function of a 1A -AR (Fig. 4B) . Given that the a 1A -AR-dependent phase of the Iso concentration-response relationship was found to be only partially dependent on the extracellular Ca 2+ and insensitive to pertussis toxin treatment, we asked whether Iso-occupancy at a 1A -AR results in Ga q activation. In a 1A -AR transduced HEK-293/EBNA cells, the selective a 1A -AR agonist A-61603 elicited concentration-dependent IP accumulation (S1 Fig.) . A-61603-stimulated IP accumulation was best described by a single phase sigmoidal equation yielding an EC 50 of 40 nM ( Table 1) . Furthermore, preincubation of those cells for 5 minutes with 10 nM of the a 1A -AR selective antagonist RS100329 significantly attenuated IP accumulation and produced a large, rightward shift in A-61603 potency. In contrast, when replicate cells were treated with Iso (up to 10 mM) no significant accumulation of IP was detected. Furthermore, IP formation in untransduced cells upon treatment with either A-61603 or Iso was not detectable (data not shown). We employed an LC-MS method to increase our detection sensitivity and to measure individual inositol phosphates rather than total IPx accumulation (Fig. 5) . In a 1A -AR transduced HEK-293/EBNA both NE and the selective a 1A -AR agonist A-61603, produced concentrationdependent increases in cellular levels of inositol phosphates IP1, IP2 and IP3 that were best described by a monophasic sigmoidal equation (Fig. 5) . On the other hand, when replicate cells were treated with Iso (up to 10 mM), no significant changes in intracellular inositol phosphates were detected. Thus, it appears that Iso occupancy at a 1A -AR biases receptor signaling toward a Ga q -independent pathway.
Iso induces Ca
Iso induces biphasic concentration-response behavior for p-ERK formation in α 1A -AR transduced HEK-293/EBNA cells
Significant efforts have been placed in understanding the role of the mitogen-activated protein kinase (MAPK) cascade in adrenoceptor signaling (e.g. in cardiomyocyte physiology, see [38] ). We decided to test whether the Iso-mediated signaling that we observed involved this signaling pathway. For this, we examined whether Iso induces ERK1/2 activation. Treatment of a 1A -AR transduced HEK-293/EBNA cells with Iso induced a dose-dependent increase of p-ERK formation (Fig. 6, filled circles) . The resulting concentration-response relationship was best fit by a biphasic model. The calculated EC 50 values were 5 nM and 6 mM for the high and low potency phases, respectively. In untransduced cells a monophasic relationship was observed (EC 50 = 1 nM, S2 Fig.) . Interestingly, in a 1A -AR transduced HEK-293/EBNA cells, A-61603 or NE yielded concentration-dependent activation of ERK that was best fit by a monophasic sigmoidal model. The measured EC50 values were 0.8 and 90 nM for A-61603 and NE, respectively (Fig. 6 , filled triangles or squares, and potency phase of response to Iso (via occupancy of b 2 -AR) and the low potency phase (via occupancy of both b 2 -AR and a 1A -AR) were quite similar for the two different readouts ( Table 1) .
Stimulation of α 1A -AR transduced HEK-293/EBNA with A-61603 and Iso leads to an increase in the level of intracellular α 1A -AR without recruitment of arrestins We next investigated whether or not a 1A -AR internalizes upon stimulation with A-61603 or ISO. In several prior studies a 1A -AR has been found to undergo constitutive, ligand independent trafficking and to internalize rather modestly (*20%) upon agonist stimulation [39] [40] [41] . Furthermore this receptor cycling involves clathrin-coated vesicles and entry to early endosomes [39] . To eliminate some of the experimental challenges and uncertainty related to detection of the modest and transient internalization of a 1A -AR, we employed constitutively active and dominant-negative forms of Rab5 and Rab11, respectively, to the analysis of a 1A -AR endocytosis using confocal microscopy. Constitutively active Rab5 Q79L enhances endocytosis and early endosome fusion, causing the formation of enlarged early endosomes, and its overexpression has been shown to inhibit transferrin recycling. Rab11 S25N is defective in GTP binding and impairs recycling by inhibiting exit from sorting endosomes (early endosomes) to the recycling endosomes and/or plasma membrane. In HEK-293/EBNA cells transfected with a 1A -AR only and stimulated with A-61603 or ISO, a 1A -AR was mostly localized at the plasma membrane, as was the case for the vehicle control (Fig. 7A) . Overexpression of Rab5Q79L caused some intracellular a 1A -AR accumulation in vehicle control cells, indicative of constitutive trafficking, as well as significant a 1A -AR accumulation upon A-61603 or ISO treatment. Overexpression of Rab11 S25N led to some accumulation in A-61603 or ISO-treated cells, not as pronounced as the one observed upon Rab5Q79L overexpression. In vehicle-treated cells, a 1A -AR appeared predominantly at the plasma membrane. To confirm the observation that stimulation with Iso led to internalization of a 1A -AR, we took advantage of a cleavable biotin labeling reagent to discern levels of surface versus internalized a 1A -AR by means of immunoprecipitation ( Fig. 7B and S3 Fig.) . Intracellular a 1A -AR could be detected at low levels in control cells (lane 3, "C+GSH") indicative of constitutive trafficking. Treatment with A-61603 caused an increase in intracellular a 1A -AR levels after 5, 30, and 60 min of treatment (lanes 4-6, "A-61603+GSH") relative to control cells (lane 3,"C+GSH"). Similarly, treatment with ISO caused an increase in the intracellular a 1A -AR (lanes 7-8, "ISO+GSH 5 or 30"), as compared to control cells (lane 3, "C+GSH"). We next examined whether Iso-induced internalization of a 1A -AR in HEK-293 cells involved the recruitment of b-arrestins. The ability of the N-terminally FLAG-tagged a 1A -ARs to trigger the translocation of GFP-tagged b-arrestins in those cells was investigated by confocal microscopy. As shown in Fig. 8 , in vehicle treated cells, the a 1A -AR was localized mainly at the plasma membrane while both b-arrestins 1 (left panels) and 2 (right panels) were homogenously distributed throughout the cytoplasmic compartment with no visible co-localization with the surface receptor. In cells expressing the a 1A -AR, stimulation with A-61603 for 30 min did not induce significant translocation of either b-arrestin-1 nor b-arrestin-2, to the plasma membrane. Similarly exposure of the same cells to Iso did not moderate levels of the receptor (*1 pmol/mg of membrane proteins) [42] . The b-AR selective agonist Iso evoked a Ca 2+ transient response in a 1A -AR_CHO cells (Fig. 9A ) that was not observed in CCR5_CHO cells used as a negative control (S4 Fig.) . The peak amplitude of Ca 2+ transient response, DF/F 0 , as a function of agonist concentration yielded a monophasic concentration-response curve with the half-maximal amplitude occurring at 20 mM Iso (Fig. 9A) . That response to Iso was blocked by preatreatment with 100 nM RO100329, but was insensitive to propranolol at 100 nM. We next examined whether Iso-mediated Ca 2+ mobilization involved formation of inositol phosphates. Stimulation of a 1A -AR_CHO cells with NE led to concentration-dependent IP accumulation with an EC 50 of 0.6 mM (Fig. 9B) . On the other hand, no IP accumulation could be detected in the same cells stimulated with Iso at concentrations up to 1 mM. Similarly, in a 1A -AR CHO cells both NE, and the selective a 1A -AR agonist A-61603, produced concentration-dependent increases in cellular concentration of inositol phosphates; IP1, IP2 and IP3 (Fig. 9D ) that were best described by a single-site sigmoidal equation. In contrast, when replicate cells were treated with Iso (up to 1 mM) no significant changes in intracellular levels of inositol phosphates could be detected. Thus, it appears that Iso occupancy at a 1A -AR biases receptor signaling to a Ga q -independent pathway. Yet, similarly to the observations made with a 1A -AR_HEK-293/EBNA cells, stimulation of a 1A -AR_CHO cells with Iso resulted in a concentration dependent increase in phospho-ERK formation (Fig. 9C) .
The amount of p-ERK formed at the maximal concentration of Iso represented 35% of the level observed in these cells when stimulated with saturating concentrations of NE or A-61603. Iso was less potent than NE and A61603 at inducing ERK activation in a 1A -AR_CHO cells (Iso: EC 50 = 17AE5 mM; NE: EC 50 = 0.13AE0.02 mM; A61603: EC 50 = 0.8 AE 0.2 nM). These results indicate that Iso is ineffective at inducing a 1A -AR-mediated Ga q coupling and PLC activation, yet shows partial agonist activity at mediating a 1A -AR induced activation of the MAPK signaling cascade.
Discussion
A search on "isoproterenol" in the PubMed database retrieves more than thirty thousand citations. This potent, b-AR-selective agonist has been extensively studied with respect to many aspects of its action at b-ARs. It has been applied frequently as a tool to verify the presence of b-ARs in cell-based systems or to elucidate the mechanism of b-AR signaling in nonrecombinant, native cells such as cardiomyocytes, adipocytes and many others, as well as in organ tissue preparations. In several of these studies the concentrations used were in the micromolar range, which may have triggered off-target effects. Dating back to the 1950s, several reports have indicated that Iso at higher concentrations can evoke a-AR-mediated responses. For instance, Furchgott [9] observed that Iso at concentrations 1-500 mM caused contraction of rabbit thoracic aorta, a tissue in which all three a 1 -AR subtypes are expressed (reviewed in [43] . These researchers also noted that the rate of shortening on addition of Iso was much slower relative to epinephrine or norepinephrine, indicating a distinct mechanism of action for Figure 7 . Stimulation of α 1A -AR transduced HEK-293/EBNA with A-61603 and Iso leads to an increase in intracellular α 1A -AR. A. HEK293 cells were transiently transfected with α 1A -AR only (top panels), or co-transfected with α 1A -AR and Rab5 variant Q79L (middle panels) or Rab11 variant S25N (bottom panels). Following serum-deprivation, cells were stimulated with vehicle, 1μM A-61603 or 1mM ISO for 2h. Cells were then fixed and analyzed by confocal microscopy. B. HEK293 cells were transiently transfected with α 1A -AR. After serum deprivation for 24h, cells were pre-treated with a membrane impermeable, disulfide-cleavable biotin reagent to label plasma membrane α 1A -AR. Cells were then left untreated, or stimulated 1 μM A-61603 or 1mM ISO for 5, 30, or 60 min. After treatment, one dish of control cells was harvested without any further manipulations (C: total α 1A -AR). The remaining seven dishes were divided into one control (C+GSH), three treated with A-61603 (A-61603+GSH) and three treated with ISO (ISO+GSH). They were stripped of surface biotin label using a reducing agent, in order to reveal internalized, labeled α 1A -AR. Samples were then analyzed by immunoprecipitation (IP) with streptavidin followed by immunoblotting (IB) with an anti-FLAG antibody.
Iso. The maximal contractile response to Iso was about 75% of that obtained for norepinephrine indicating that Iso acted as a partial agonist. Our studies of HEK-293/EBNA cells with transient low expression levels of a 1A -ARs cells, to mimic tissues that possess both a 1A and b-ARs, provide for the first time a mechanism to account for Furchgott's original observations. In those cells, a biphasic dose-response relationship was found for Iso-evoked calcium transients. The high potency phase of the response was blocked by non-selective as well as b 2 -selective antagonists, while the low potency phase was sensitive only to a 1A -AR-selective antagonists. Remarkably, Ca 2+ transient responses to Iso mediated by a 1A -ARs exhibited a time course distinctly slower than those seen with prototypical a 1A AR agonists (NE, A-61603) that are highly efficacious for IP x formation responses and considered typical for Ga q -initiated signaling. Responses to Iso showed delayed onset by 5 to 10 seconds and were much slower to rise in amplitude. Moreover, Iso was a partial agonist at a 1A -ARs as recorded by this readout. Finally, the observed Ca 2+ transients exhibited almost complete desensitization, unlike responses to NE. These data taken together indicate a mechanism of action distinct from classical Ga q coupling for Iso at the a 1A -AR, and suggest functional selectivity (effector signaling bias) for the activity of this agonist. Agonist occupancy of any given GPCR may trigger signaling events through activation of more than one physiological response cascade. For instance, a 1A -AR is widely known to couple to phospholipase C. However, this receptor also reportedly mediates activation of several other effectors such as phospholipase D, phospholipase A 2 , adenyl cyclase and several members of the MAPK family (reviewed in [44] ). Certain synthetic agonists have been found to be capable of biasing GPCR signaling toward a particular proximal effector. This ability of a ligand to direct an activated receptor state to a particular effector output has been termed "functional selectivity" or "effector bias" (for reviews see [45] [46] [47] [48] . Within the adrenoceptor family, there is both pharmacological and biophysical evidence for agonist dependent effector bias at b-ARs. Signaling bias has been shown for several ligands at both b 1 -and b 2 -AR toward adenyl cyclase and MAPK [49, 50] .
We observed that Iso occupancy of a 1A -AR caused Ca 2+ transient responses in HEK-293/EBNA cells without observable PLC activation: no formation of individual inositol phosphates or IP accumulation was detected in these cells under the same conditions. Unexpectedly, Iso occupancy of a 1A -AR also mediated ERK1/2 activation, suggesting that Ga q coupling is not required for ERK activation by Iso. Adding to the surprise, A-61603 appeared to be significantly more potent at activating ERK as compared to activation of Ga q , whereas NE displayed equivalent potencies for both responses. Taken together, the signaling patterns observed with these agonists appear to reveal a spectrum of partially overlapping effector coupling mechanisms. Iso, and the imidazoline A-61603, appear to have a bias toward MAPK activation. Moreover, for A-61603 there seems to be greater receptor reserve or response amplification for the pERK formation response. The a 1A -AR has also been found to regulate mitogenic responses, but it is not clear if this activity is downstream of Ga q engagement [38, 51] . Minneman and co-workers have in fact reported NE activation of a 1A -AR-mediated MAPK phosphorylation in rat PC12 cells [51, 52] , independently of both Ga q -induced Ca 2+ mobilization and PKC activity [53] . The same group later showed that deletion of the first three amino acids from the third intracellular loop not only uncouples the receptor from Ga q , but also abolishes activation of the MAPK pathway [54] . It was suggested that these two pathways operate independently from one another, yet may depend on similar structural elements of agonist-occupied receptor. Several lines of evidence seem to indicate that in mouse cardiomyocytes, the a 1A -AR-mediated MAPK activation may not be associated with activation of Ga q pathway [38, 55] . a 1A -AR /a 1B -AR double-knockout mice also developed heart failure after transverse aortic constriction, and reconstitution of a 1A -AR signaling in cardiomyocytes from those animals rescued them from NE-induced apoptosis [56] . The expected IP generation was not detectable in those cardiomyocytes with reconstituted a 1A -AR function or in wild-type mouse cardiomyocytes, pointing at a non-Gq signaling mode for this receptor in myocardial function. More importantly, Huang et al. (2007) reported that a 1A -AR stimulation of an ERK-mediated pathway is critical for cardiomyocyte survival. Our data support those findings as well as provide further evidence indicating that Iso occupancy of a 1A -AR induces an active receptor "state" that leads to MAPK pathway activation without activating the canonical Ga q pathway.
Our previous studies of Ga q coupling defective variants of a 1A -AR combined with examination of the effects of Ca(II) channel blockers uncovered cross-talk between a 1A -AR and b 2 -AR that leads to potentiation of a Ga q -independent signaling cascade in response to a 1A -AR activation [27] . Moreover, this signaling event was accompanied by Ca(II) mobilization with unusual kinetics mirroring the kinetics observed for Iso induced Ca(II) mobilization in a 1A -AR_HEK293/EBNA cells. Interestingly, in the presence of a b-AR-selective antagonist, the amplitude of the a 1A -AR-mediated Ca 2+ transient response to Iso (i.e. the lower potency phase of the Iso concentration-effect relationship) was not only lower than expected, but also occurred with a significant delay in onset. This may indicate a synergy occurs between these receptors in generating the lower potency phase of response. Recent reports provide an independent line of evidence for a 1A -AR-mediated activation of endocytic pathway that leads to phosphorylation of ERK1/2, independent of Ga q /PLC/PKC signaling [57, 58] . In one study, dynamin mutants were employed to induce trafficking defects, along with various molecules disrupting actin and tubulin organization. Liu and coworkers show that a 1A -AR induced activation of ERK1/2, but not p38 MAPK, was dependent on cytoskeleton and actin organization. On the other hand, a 1A -AR-induced activation of PKC and C-Raf was not affected by endocytosis disruption. Neither PKC nor PLC inhibition blocked a 1A -AR induced activation of ERK1/2 [57] . More recently, the spatial-temporal characteristics of receptor internalization and ERK1/2 activation in response to stimulation of a 1A -AR in HEK293 were investigated in combination with various inhibitors of PKC, receptor internalization as well as b-arrestin 2 silencing and differential patterns were discovered for Gq/PKC dependent as compared to the Ga q -independent signaling cascade. The rapid phosphorylation of ERK1/2 was dependent on activation of PKC downstream of Ga q and resulted in pERK1/2 translocation into the nucleus while sustained activation of ERK1/2 that was limited to cytoplasmic compartment, was independent of PKC but dependent on receptor internalization into acidified endosomes and was mediated by b-arrestin 2 [58] . Together, those findings and our own data provide strong evidence that a 1A -AR can induce activation of ERK1/2 in a manner that is independent of the canonical Ga q /PLC/PKC signaling cascade but involves receptor internalization. We also found that Iso is a biased agonist that can preferentially stimulate a 1A -AR mediated activation of MAPK signaling pathway through receptor internalization and without induction of Ga q coupling. Although, our study did not conclusively detect Iso induced a 1A -AR association with b-arrestins after agonist application, involvement of b-arrestin 2 in mediating this response cannot be ruled out. Several groups have demonstrated that agonist-mediated GPCR association with b-arrestin leads to G protein-independent activation of the MAPK pathway [23] . In fact, it has been shown recently that NE occupied a 1A -AR associates although weakly with both b-arrestin-1 and 2, but coupling to the MAPK pathway was not investigated in this study [59] . Further studies including b-arrestin knock-downs will be needed to fully determine whether or not this signaling mechanism is actually dependent on b-arrestin 2.
On the other hand, it has been recently shown that a genetic variant of the a 1A -AR transactivates EGFR via a b-arrestin1-dependent mechanism similarly to the b1-AR mediated EGFR transactivation and leads to ERK1/2 activation downstream of EGFR [60] [61] [62] . Transactivation of EGFR by b-AR confers cardioprotection [61, 62] suggesting that transactivation could be involved in the antiapoptotic and cardioprotective activity of the a 1A -subtype. We have examined this potential mechanism in mediating the Iso induced a 1A -AR stimulation of ERK1/2 using EGFR inhibitor AG1478 and found that activation of ERK was not affected by the inhibition of EGFR (data not shown). Further studies may be needed to fully explore this mechanism.
Our observations differ from those of Sun et al., who reported that Iso evoked biphasic dose-effect relations in MAPK activation [24] . The observed biphasic behavior was attributed to distinct processes by which MAPK activity is modulated, either through regulation of adenylyl cyclase by b 2 -AR/Ga s , or by formation of a macromolecular complex containing Interestingly, we observed that in the presence of a b-AR-selective antagonist, the kinetics of Iso-evoked a 1A -AR-mediated Ca(II) transient response was much slower and with the greatest delay (Fig. 2C) , and the the amplitude of the a 1A -AR-mediated Ca(II) transient (i.e. the lower potency phase of the Iso concentration-effect relationship- Fig. 1B ) was lower than expected, indicating synergy between these receptors in generating the low potency response phase. This is consistent with previously published results with wild-type a 1A AR and Gaq signaling deficient variants expressed in HEK EBNA cells with endogenous expression of b2 AR that showed that b2 AR signaling actually potentiates a 1A AR-mediated Ca(II) response and the potentiation was most striking in cells expressing Gaq defective mutants [27] . Furthermore, this potentiation of Ca(II) transient was most evident for the signal not blocked by Xestospongin C/2-APB application, and consistent with the non-Gq /ERK signaling cascade.
Nonetheless, Iso can also induce intracellular Ca 2+ mobilization (as well as ERK activation)
in CHO cells lacking b 2 -AR expression, upon stable expression of a 1A -ARs (Fig. 9) and in a 1A -AR_ HEK-293/EBNA cells in presence of b-AR antagonists indicating that this signaling is not dependent on b 2 -AR. The potency of Iso at mediating the Ca(II) response in a 1A -AR_ CHO cells (EC 50 = 18 AE 8 mM) was somewhat lower than the potency of the second phase observed in HEK-293/EBNA cells (EC 50 = 2.6 mM). This response was blocked by an a 1A -AR-selective antagonist, but was not sensitive to the b-AR selective antagonist propranolol. On the other hand, in untransduced HEK-293/EBNA cells expressing b 2 -ARs which lack a 1A -AR expression, we observed only a high potency, monophasic response to Iso for both intracellular Ca 2+ mobilization and p-ERK formation. Although, this study utilizes a model system where a 1A -AR was transiently expressed at low, physiological levels together with endogenous b2-AR in HEK293(EBNA), evidence already exist suggesting that similar mechanism may be utilized in physiologically relevant settings such as e.g. cardiomyocytes where both receptors are co-expressed. Sabri et al observed that in rat cardiomyocytes ERK activation in response to NE was mostly mediated by a 1 -AR receptor and only a minor component of ERK was activated by b-AR [63] . In the same cardiomyocytes Isoproterenol induced p38-MAPK, cAMP and enhanced contractile function at concentrations that retained b2-AR selectivity while ERK1/2 activation required 100 fold higher dose (of 10 mM). On the other hand Zinterol induced ERK activation at b2-AR selective concentrations indicating that receptor reserve was not the problem. Role of other adrenoceptors in mediating ERK1/2 activation in response to ISO was not addressed. In a more recent publication cardioprotective and cardiotoxic effects of Isoproterenol on feline cardiomyocytes in vitro and in vivo have been reported. The cardiotoxic effect was found to be mediated by PKA and sarcoplasmic Ca(II) overload downstream of b-AR since the effect could be blocked by PKA inhibitory peptide and b-AR antagonist. On the other hand the cardioprotective effect was attributed to ERK activation mediated by EPAC downstream of b-AR [64] . Although strong evidence implicating EPAC in the Iso mediated cardioprotective signaling was presented, the response was induced by high non-selective Iso concentrations (10 mM) and could not be fully blocked by b-AR antagonist metoprolol (at 20 mg/kg body weight) implicating potentially involvement of other non-b-AR receptor. Interestingly, earlier studies performed with a 1A/B -AR KO mice reported that a 1A -AR induced ERK signaling pathway is cardioprotective and required for cardiomycocyte's survival [38] . The hearts of AB KO mice had worse fibrosis and increased cardiac cell death as compared to those from wild-type littermates when pressure loaded, while NE or Iso treatment of cultured cardiomyocytes from the KO mice resulted in more necrosis and apoptosis. The enhanced susceptibility to cell death could be rescued by reintroduction of a 1A -AR but not a 1B -AR and required activation of ERK1/2. Similarly, in neonatal rat myocytes, a 1 -AR stimulation inhibited apoptosis caused by cAMP, and was abolished by a MEK inhibitor suggesting a role for ERK1/2 [65] . Recent evidence points also at potential protective effects of a 1A -AR signaling in the CNS (reviewed in [66] ). Chronic a1A-AR stimulation was shown to increase neurogenesis, enhance learning and memory while also protecting the brain from anoxia and traumatic injury, seizures, and age-dependent neurodegeneration.
In conclusion, we have found that isoproterenol is a low potency agonist at a 1A -ARs, and appears to manifest effector bias when bound at a 1A -AR, inducing activation of a Ga q -independent signaling cascade. This may explain decades-old observations of unusual properties reported for this ligand. As discussed earlier, in cardiomyocytes, induction of the MAPK pathway via a 1 -ARs has been shown to protect those cells from apoptosis [38] . In contrast, increased Ga q signaling induced cardiac hypertrophy and loss of b-AR inotropic responsiveness [67] , ultimately leading to heart failure [68] . Thus, our discovery of the apparently biased coupling at a 1A -AR of the agonist ISO, adds pharmacological and chemical support for the potential to identify a novel class of therapeutics for treatment of heart failure [56, 69] . Although, isoproterenol itself will not be a drug candidate in this respect, it can serve as benchmark for the search of molecules with such pharmacological profile. Meanwhile, caution should be taken while using isoproterenol in non-recombinant, undefined systems, with proper controls and/or selective antagonists included in those experiments to minimize confounds attributable to the involvement of a-ARs in monitored outcomes. 
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